Physician profile
Osama E Sayegh
NPI 1235196320
$2,967.99
in general payments reported to CMS, 2019-2025
29 companies · $716 in 2025
The $716 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $24.81 · 2021: $169 · 2022: $223 · 2023: $961 · 2024: $709 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $643.59 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $366.24 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $282.68 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $232.13 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $202.03 | 2023-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $160.57 | 2021-2023 | Ingrezza |
| Myriad Women'S Health, INC. | $118.07 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $110.58 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $88.52 | 2025 | Crexont |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.86 | 2021-2023 | Xifaxan |
| Amarin Pharma, INC. | $60.29 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $51.66 | 2023-2024 | Nuedexta, Rexulti |
| Abbvie INC. | $51.04 | 2019-2020 | |
| Abbott Laboratories | $50.33 | 2023-2025 | Freestyle Libre 3, Jeti Peripheral Catheter |
| Braeburn INC. | $48.38 | 2025 | Brixadi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $45.82 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $43.52 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $42.41 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.31 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $39.62 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $35.82 | 2019 | |
| Lilly USA, LLC | $30.95 | 2021-2024 | Amyvid |
| Takeda Pharmaceuticals U.S.A., INC. | $25.84 | 2023 | Cuvitru |
| Mylan Specialty L.P. | $24.00 | 2024 | Yupelri |
| Dynavax Technologies Corporation | $21.36 | 2022 | |
| Pfizer INC. | $20.25 | 2024 | |
| Ironwood Pharmaceuticals, INC | $19.75 | 2019 | |
| Genentech USA, INC. | $19.71 | 2022 | |
| Alkermes, INC. | $18.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.